NBTX Nanobiotix S.A.

QT48

Latest market price

31.37

-2.43-7.19%

Overview Short InterestFilings

NBTXQT48Nanobiotix S.A.·NASDAQ

Overview Short InterestFilings

31.37-7.19%

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

TRAX-0.33%$45.08 NVAX-3.72%$10.08 NUVB-0.21%$4.76 KLRA-4.10%$12.86 REPL+1.27%$17.61 STOK-0.23%$26.29 QURE-1.86%$24.83 NTLA-5.74%$12.47

Snapshot

Index	—	P/E	—	EPS (ttm)	-0.58	Insider Own	—	Shs Outstand	50.95M	Perf Week	6.85%

Market Cap	1.60B	Forward P/E	—	EPS next Y	-0.22	Insider Trans	—	Shs Float	41.73M	Perf Month	12.44%

Enterprise Value	1.59B	PEG	—	EPS next Q	0.07			Short Float	0.47%	Perf Quarter	-19.34%

Income	-27.00M	P/S	48.43	EPS this Y	—			Short Ratio	1.30	Perf Half Y	-10.68%

Sales	33.00M	P/B	—	EPS next Y	—	ROA	-41.20%	Short Interest	196.51K	Perf YTD	35.68%

Book/sh	-0.75	P/C	12.58	EPS next 5Y	—	ROE	—	52W High	57.14 -45.10%	Perf Year	74.37%

Cash/sh	2.49	P/FCF	—	EPS past 3/5Y	—	ROIC	-40.79%	52W Low	17.37 80.60%	Perf 3Y	401.92%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	87.58% 61.54%	Gross Margin	—	Volatility	5.64% 6.32%	Perf 5Y	145.27%

Dividend TTM	—	EV/Sales	48.28	EPS Y/Y TTM	—	Oper. Margin	-367.66%	ATR (14)	2.19	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	1.44	Sales Y/Y TTM	-25.00%	Profit Margin	-617.88%	RSI (14)	55.43	Recom	2.25

Dividend Gr. 3/5Y	—	Current Ratio	1.44	EPS Q/Q	-497.07%	SMA20	19.27%	Beta	0.89	Target Price	38.00

Payout	0.00%	Debt/Eq	—	Sales Q/Q	-80.00%	SMA50	-3.56%	Rel Volume	1.58	Prev Close	33.80

Employees	97	LT Debt/Eq	—	Earnings	Apr 27	SMA200	-7.31%	Avg Volume	149.33K	Price	31.37

IPO Date	Dec 11, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-64.70% 268.93%	Net Debt/EBITDA	—	Volume	235,667	Change	-7.19%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-04-26	Reiterated	Leerink Partners	Outperform	$26 → $46
May-01-26	Reiterated	UBS	Neutral	$30
Nov-25-25	Reiterated	Leerink Partners		$14 → $26
Sep-18-25	Reiterated	Leerink Partners		$9.00 → $14
Aug-27-24	Initiated	Guggenheim	Buy	$12

Latest News· Times ET

Oct-26-26

Oct-26-2607:31PM

Nanobiotix (ENXTPA:NANO) Could Be 46% Undervalued As Melanoma Trial Results LandYahoo

Oct-24-26

Oct-24-2607:00AM

NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanomaglobenewswire.com

Oct-21-26

Oct-21-2606:12AM

Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On WednesdayBenzinga

Oct-20-26

Oct-20-2604:15PM

Voting Rights and Shares Capital of the Companyglobenewswire.com

Oct-10-26

Oct-10-2601:11PM

Nanobiotix (ENXTPA:NANO) Could Be 59% Undervalued After Its CFO ChangeYahoo

Oct-03-26

Oct-03-2605:01AM

Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Time to Sell?defenseworld.net

Oct-02-26

Oct-02-2606:21AM

Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase – Still a Buy?defenseworld.net

Oct-01-26

Oct-01-2604:15PM

NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officerglobenewswire.com

Sep-24-26

Sep-24-2604:15PM

NANOBIOTIX Provides First Half 2026 Operational and Financial Updateglobenewswire.com

Sep-22-26

Sep-22-2604:15PM

Voting Rights and Shares Capital of the Companyglobenewswire.com

Sep-21-26

Sep-21-2604:29AM

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Recommendation of “Moderate Buy” from Analystsdefenseworld.net

Sep-17-26

Sep-17-2601:06PM

Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks?Yahoo

Sep-14-26

Sep-14-2602:00AM

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung CancerYahoo

Sep-09-26

Sep-09-2604:15PM

NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conferenceglobenewswire.com

Sep-02-26

Sep-02-2606:26AM

Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On WednesdayBenzinga

Company

Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	33	-8	39	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	—	—	—	—	—	—
Gross Profit	33	-8	39	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	23	22	24	—	—	—	—	—	—
Research and Development	26	44	42	—	—	—	—	—	—
Other Operating Expense	-3	0	2	—	—	—	—	—	—
Operating Income	-12	-74	-29	—	—	—	—	—	—
Interest Expense	12	9	9	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-3	9	-5	—	—	—	—	—	—
Net Income Before Taxes	-27	-74	-43	—	—	—	—	—	—
Income Taxes	0	0	0	—	—	—	—	—	—
Consolidated Net Income	-27	-74	-43	—	—	—	—	—	—
Net Income From Continuing Operations	-27	-74	-43	—	—	—	—	—	—
Net Income	-27	-74	-43	—	—	—	—	—	—
EPS (Recurring)	-0.56	-1.56	-1.17	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.56	-1.56	-1.17	—	—	—	—	—	—
EPS (Diluted)	-0.56	-1.56	-1.17	—	—	—	—	—	—
EBITDA	-14	-72	-25	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	33.63	-16.86	6.91	—	—	—	—	—	—
Gross Margin	100.00	100.00	100.00	—	—	—	—	—	—
Operating Margin	-36.36	925.00	-74.36	—	—	—	—	—	—
Net Margin	-81.82	925.00	-110.26	—	—	—	—	—	—
Shares Outstanding	48	47	37	—	—	—	—	—	—
Market Capitalization	1,110	135	269	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.